(101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
(108-20) A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
(127-21) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors
(130-21) A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
(131-17) A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)
(131-21) Tumor-Agnostic precision immuno-oncology and somatic targeting rational for you (tapistry) Phase II platform trial
(155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation
(160-21) A Phase 1 Study of ZN-c3 as a Single Agent in Subjects with Solid Tumors
(162-20) A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer
(173-18) Perioperative Mindfulness Proposal
(178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
(181-21) Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects with Advanced Triple-Negative Breast Cancer After Prior Therapy
(182-20) 18F-FLUORESTRADIOL (FES) PET/CT COMPARED TO STANDARD-OF-CARE IMAGING IN PATIENTS WITH BREAST CANCER (Phase 2 clinical trial, appropriate for patients with breast cancer.)
(187-17) Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
(187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer
(188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors
(188-20) A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
(196-21) A Phase 1 b/2 study of repotrectinib in comination with other anticancer therapies for the treament of subjects with KRAS-Mutant advanced solid tumor (TRIDENT-2)
(205-19) Study to Assess AFM24 in Advanced Solid Cancers
(209-20) First-In-Human Dose-Escalation Study of SRP1002 in Patients with Advanced-Stage Solid Tumors
(213-20) A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
(221-19) Study of GNX102 in Patients With Advanced Solid Tumors
(231-20) A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies
(243-20) Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors
(206-21) The Impact of Cerianna PET/CT Results on the Therapeutic Decision in Patients with Known or Suspected Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn more about these or other clinical trials, please call 949-764-5543